Global Cell and Gene Therapy CDMO Market is projected to witness a CAGR of 25% to reach $5 billion by 2025 - Growing Cases of Cancer and Other Targeted Diseases

Robust CGT pipeline with an increasing number of product approvals, healthy support from large pharmaceutical and biotechnology companies and consistent investor enthusiasm (~$20 billion raised in 2020) is projected to boost the demand for CGT services. Growing pipeline of therapies are nearing regulatory decisions. Out of 1,220 ongoing clinical trials in 2020, 152 were in Phase 3 - FDA and EMA predict approval of 10-20 cell and gene therapies each year by 2025.

An Increasing Demand for Full-service/One-stop-shop CDMOs

Full-service CDMOs which can assist with both development and manufacturing are in high demand. Much of the Cell and Gene Therapy development as of late has been from smaller biotechnology companies or research universities who depend on CDMOs from preclinical development through packaging.

"There is a high demand for Cell and Gene Therapy CTDMOs who can offer integrated development, manufacturing, and testing services. For companies operating in CGTs, outsourcing manufacturing and testing operations to a capable CTDMO can reduce development timelines, provide supplementary capacity and ultimately reduce costs."-Senior Director, Tier 1 CGT CDMO, United States

Substantial Outsourcing in Cell and Gene Therapy Market due to Lack of Internal Capabilities

The current level of outsourcing in CGT market exceeds 60% which is far above the level of outsourcing seen in overall pharmaceutical and biologics segment. Cell & Gene Therapy is a complex segment requiring high level of domain expertise. Also, it has costly production and different manufacturing process/infrastructure requirements as compared to traditional small molecules. Big pharmaceutical companies currently lacks production-ready infrastructure and are increasingly looking for CGT CDMOs to enter or expand their presence in this rapidly growing CGT CDMO market. Moreover, growing influx of small biotech companies in the global market with limited/no manufacturing capabilities and/or with development expertise further provides ample growth opportunities for the Cell and Gene Therapy CDMO market.

Geographic Overview: North America is the Largest and Fastest Growing Market

North America is estimated to witness the fastest growth and continue its dominance in the coming 5 years owing to growing manufacturing capacity for CGTs, favorable regulatory approval process, growing CGT approvals per year, and strong product pipeline of CGTs in USA.

Competitive Landscape Analysis: Cell and Gene Therapy CDMO Market

The global Cell and Gene Therapy CDMO market is marked by the presence of both established players and several small and mid-sized players. Some of the major and leading players operating in the CGT CDMO market are Lonza, Catalent, Patheon, Wuxi Advanced Therapies and Charles River Laboratories. Other promising players in the market are Vive Biotech, SK Bioscience, Fujifilm, Vibalogics, Exothera, Takara, Oxford Biomedica, Viralgen and AGC Biologics, among several others.

Get Detailed Insights on Cell and Gene Therapy (CGT) CDMO Market with a Sample Report @ https://meditechinsights.com/cell-and-gene-therapy-cdmo-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Healthcare IT, MedTech, Medical Devices & Pharma Services.

This release was published on openPR.